Stay on target.
Tumors adapt; effective therapy needs to adapt with them.
The problem: We can’t predict patient responses to cancer drugs, and trial-and-error intervals are too long.
Watch how it works
Our Team
Eran Oren
Biosensor lead
Medical technology leader experienced in managing complex interdisciplinary projects.
Graduate of the IDF “Talpiot” program and holds an MSc from the Weizmann Institute.
Dr. Eldad Elnekave
Founder and CEO
Memorial Sloan Kettering Cancer Center Fellowship-Trained. Founded and directed the clinic for Interventional Oncology at Davidoff Cancer Center 2014-2022, and at Shaare Tzedek Medical Center 2022-2024.
Founding Chief Medical Officer of Zebra Medical 2014-2021 (acquired: NNOX). Published in high-impact journals such as Nature Medicine, JAMA Oncology, Annals of Surgical Oncology, Journal of Vascular and Interventional Radiology.
Be’eri Katznelson
Micro-engineering lead
Mr. Katznelson has over 40 years of experience leading development of advanced micro-mechanics and robotic solutions in Defense organizations and Health-tech enterprises.
Our Advisory Board
For patients:
Patients receive treatments that may not work, yet response is assessed only every few months—often after tumors have already progressed.
This delay costs time, exposes patients to unnecessary side effects, and fails to keep pace with tumor evolution.
For Pharma:
Less than 5% of cancer drugs progress from Phase I trials to FDA approval, with trial failures costing over $60 billion annually—the largest expense in drug development.
The process is slow—averaging 10 years per drug and 3.5 years per trial phase—creating a bottleneck that delays new drug evaluation and access to effective treatments.
The solution:
We need real-time, dynamic therapy assessment. Listen Therapeutics delivers that.